Unlock instant, AI-driven research and patent intelligence for your innovation.

Fusion protein capable of degrading amyloid beta peptide

A technology of fusion protein and amyloid, applied in the field of neurodegenerative diseases and medical treatment

Inactive Publication Date: 2010-03-10
ASTRAZENECA AB
View PDF17 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, even passive immunization against β-peptides may cause undesired side effects in human patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fusion protein capable of degrading amyloid beta peptide
  • Fusion protein capable of degrading amyloid beta peptide
  • Fusion protein capable of degrading amyloid beta peptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0158] Description of protein domains

[0159] The extracellular domain of neprilysin is defined as amino acids 51-749 (excluding the first methionine) (SEQ ID NO: 1-4). There are two polymorphisms leading to the identified amino acid differences in this domain, and the amino acid sequences of the different variants are depicted in SEQ ID NO: 1-4.

[0160] IDE (Insulin Degrading Enzyme) is a 1018 amino acid long protein (SEQ ID NO: 5). Splice variants and polymorphic variants of IDE are described. In one splice variant, one exon was replaced with another exon of the same size, which encoded a peptide sequence similar to the "wt" exon (described in SEQ ID NO: 6). This variant has been described to be less efficient at degrading insulin and A[beta]. There are several polymorphisms in the described IDE gene which cause amino acid differences identified in this domain: D947N, E612K, L298F and E408G (numbering according to SEQ ID NO: 5). All combinations of these polymorphisms ...

Embodiment 2

[0164] Instructions for construction of the gene encoding the fusion protein Fc-neprilysin

[0165] The gene encoding the extracellular domain of neprilysin fused to the gene encoding the Fc domain of IgG2 was produced synthetically (GeneArt). The complete gene (encoding Fc-neprilysin) including the signal sequence was transferred from the GeneArt vector (pCR-Script, pGA4 or pUC-Kana) to the Gateway donor vector. The Gateway Donor Vector was used to introduce the complete gene into several expression vectors. By using the Gateway system, transfer from a donor vector to an expression vector can be performed using recombination rather than restriction enzymes. The mammalian expression vectors studied are mainly pCEP4, pEAK10, pEF5 / FRT / V5-DEST and pcDNA5 / FRT / TO (Gateway adapted). All of these are standard mammalian expression vectors based on the CMV promoter (pCEP4, pEAK10 and pcDNA5 / FRT / TO) or the EF-la promoter (pEF5 / FRT / V5-DEST). After all cloning steps the gene was sequen...

Embodiment 3

[0167] Instructions for Construction of Genes Encoding Fusion Proteins Fc-IDE and Fc-ECE1

[0168] The genes encoding the enzymes IDE and ECE1 fused to the gene encoding the Fc domain of IgG2 were produced synthetically. Complete genes (encoding Fc-IDE and Fc-ECE1 fusion proteins including signal sequences) were transferred from the initial cloning vector (pCR-Script, pGA4 or pUC-Kana) to the Gateway donor vector. The Gateway Donor Vector was used to introduce the complete gene into several expression vectors. The mammalian expression vectors studied are mainly pCEP4, pEAK10, pEF5 / FRT / V5-DEST and pcDNA5 / FRT / TO (Gateway adapted). All of these are standard mammalian expression vectors based on the CMV promoter (pCEP4, pEAK10 and pcDNA5 / FRT / TO) or the EF-la promoter (pEF5 / FRT / V5-DEST). Genes were sequenced after all cloning steps to confirm DNA efficiency.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates fusion proteins and their use in enzymatic treatment of Alzheimer's disease patients. Said fusion protein has the formula M-A, capable of degrading amyloid beta peptide at one or more cleavage sites in its amino acid sequence, wherein M is a protein componentthat prolongs the half-life of the fusion protein, and A is a protein component that cleaves the amyloid beta peptide.

Description

[0001] The present invention relates to fusion proteins and their use in the enzyme therapy of Alzheimer's disease patients. The fusion protein includes a component that cleaves the amyloid beta (Aβ) peptide, another component that modulates half-life in plasma; and optionally, a third component that links the first two components. Background of the invention [0002] The present invention relates to a method for preventing the formation and / or growth of amyloid plaques by reacting amyloid peptides with enzymes that specifically recognize amyloid peptides and inactivate them by degradation or modification. The present invention further relates to a method of treating Alzheimer's disease by administering optimized amyloid peptide degrading enzymes with improved catalytic activity and / or selectivity and prolonged activity in plasma. The present invention also relates to the field of medical therapy, in particular to the field of neurodegenerative diseases, and provides a method ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/48A61K38/48C07K19/00A61P25/28C12N9/64
CPCC07K14/4711C12N9/6421A61K47/48507A61K38/36A61K47/6835A61P25/00A61P25/16A61P25/28A61P43/00
Inventor C·安德松P·-O·弗雷斯克加德
Owner ASTRAZENECA AB